Hashimoto Thyroiditis
An autoimmune disease where the immune system attacks and slowly destroys the thyroid gland, eventually leading to low thyroid hormone levels (hypothyroidism).
Emergency Management: Myxedema coma requires immediate ICU admission, IV Levothyroxine (and sometimes IV Liothyronine), IV hydrocortisone (until adrenal insufficiency is ruled out), and supportive care for hypothermia and hypoventilation.
Hashimoto Thyroiditis is an autoimmune disorder characterized by chronic lymphocytic infiltration of the thyroid gland, leading to the gradual destruction of thyroid follicles. It is the most common cause of primary hypothyroidism in iodine-sufficient regions. The resulting loss of functional thyroid tissue leads to decreased production of thyroid hormones (T3 and T4).
Detailed Overview
Hashimoto Thyroiditis represents a classic organ-specific autoimmune disease. It often presents insidiously, with patients remaining euthyroid for years before progressing to subclinical, and eventually overt, hypothyroidism. Goiter is a common physical finding due to lymphocytic infiltration and TSH-mediated compensatory hypertrophy. Diagnosis relies on the presence of circulating anti-thyroid peroxidase (anti-TPO) antibodies. The clinical significance lies in its widespread systemic effects when hypothyroidism develops, impacting metabolism, cardiovascular health, and neurocognition.
Epidemiology & Demographics
The most common cause of hypothyroidism in the US. Prevalence is approximately 5% in Caucasian populations. Striking female predominance with a female-to-male ratio of 7-10:1. Peak incidence occurs between 30 and 50 years of age.
Etiological Mechanism
A complex interplay of genetic susceptibility (HLA-DR3, HLA-DR5, CTLA-4, PTPN22 polymorphisms) and environmental triggers. The immune system loses tolerance to thyroid autoantigens, primarily Thyroid Peroxidase (TPO) and Thyroglobulin (Tg).
Primary Causes
Autoimmune destruction mediated by T-cells and B-cells. Environmental triggers may include high iodine intake, viral infections, stress, and radiation exposure. Associated with other autoimmune conditions (Type 1 Diabetes, Celiac disease).
The pathogenesis involves CD4+ T-cell activation against thyroid antigens, recruiting CD8+ cytotoxic T-cells and B-cells. CD8+ T-cells directly destroy thyroid follicular cells via perforin/granzyme and Fas-mediated apoptosis. B-cells differentiate into plasma cells, producing autoantibodies (anti-TPO and anti-Tg). Anti-TPO antibodies fix complement and cause antibody-dependent cell-mediated cytotoxicity (ADCC). The persistent immune attack leads to the replacement of normal thyroid parenchyma with dense lymphocytic infiltrates, lymphoid germinal centers, and fibrosis (Hürthle cell metaplasia). As functional follicles are destroyed, T3/T4 levels drop, removing negative feedback on the pituitary, resulting in elevated TSH levels.
Diagnostic Criteria & Guidelines
Diagnosis is established by the presence of primary hypothyroidism (Elevated TSH, Low Free T4) in combination with positive anti-TPO or anti-Tg antibodies. In euthyroid patients with a goiter, positive antibodies alone suggest Hashimoto's.
Levothyroxine (synthetic T4). Starting dose: 1.6 mcg/kg/day (typically 100-125 mcg daily). Take on an empty stomach, 30-60 minutes before breakfast, or at bedtime. For elderly patients or those with coronary artery disease, start lower at 25-50 mcg daily and titrate slowly.
Second-Line & Adjunctive Therapy
No universally accepted second-line for Hashimoto's. Desiccated thyroid extract (e.g., Armour Thyroid) or Liothyronine (synthetic T3) are generally not recommended by guidelines due to unphysiologic T3/T4 ratios but are occasionally used in patients whose symptoms persist despite normal TSH on levothyroxine.
Surgical & Procedural Management
Thyroidectomy is rarely indicated. May be performed for a massive goiter causing compressive symptoms (dysphagia, tracheal deviation) or if primary thyroid lymphoma or coexisting malignancy is suspected.
Patient Counseling & Advice
Levothyroxine must be taken daily, exactly as prescribed, without food or other medications (especially iron, calcium, or PPIs) that interfere with absorption. It is a lifelong replacement therapy.
Follow-Up & Monitoring Schedule
Check TSH every 6-8 weeks after initiating or changing the Levothyroxine dose until euthyroid (target TSH 0.5 - 4.5 mIU/L). Once stable, check TSH annually.
Preventive Strategies
No known preventive measures. Screening TSH is recommended for pregnant women or those with other autoimmune diseases.
Excellent. With appropriate Levothyroxine replacement, patients have a normal life expectancy and complete symptom resolution. The gland often eventually shrinks and becomes atrophic.